Mil­li­poreSigma re­ceives CRISPR patent in China

BioSpectrum (Asia) - - SUPPLIER NEWS -

Mil­li­poreSigma, a leader in genome edit­ing, has an­nounced that the Chi­nese Patent Of­fice has is­sued a no­tice grant­ing Mil­li­poreSigma’s patent ap­pli­ca­tion for the com­pany’s CRISPR tech­nol­ogy used in a ge­nomic-in­te­gra­tion method for eu­kary­otic cells. Mil­li­poreSigma, which has a 13-year his­tory in the genomeed­it­ing field, has re­lated patent fil­ings for its in­ser­tion CRISPR method in the US, Brazil, In­dia and Ja­pan. The com­pany al­ready has had sim­i­lar key patents granted in Australia, Canada, Europe, Is­rael, Singapore and South Korea.

This forth­com­ing patent in China cov­ers chro­mo­so­mal in­te­gra­tion, or cut­ting of the chro­mo­so­mal se­quence of eu­kary­otic cells such as mam­malian and plant cells and in­ser­tion of an ex­ter­nal or donor DNA se­quence into those cells us­ing CRISPR. Sci­en­tists can re­place a dis­ease-associated mu­ta­tion with a ben­e­fi­cial or func­tional se­quence, a method im­por­tant for cre­at­ing dis­ease mod­els and gene ther­apy. Ad­di­tion­ally, the method can be used to in­sert trans­genes that la­bel en­doge­nous pro­teins for vis­ual track­ing within cells.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.